{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:00:56Z","timestamp":1792267256278,"version":"4.4.0"},"reference-count":153,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Distant metastasis is the principal cause of mortality for breast cancer patients. Targeting specific mutations that have been acquired during the evolution process of advanced breast cancer is a potential means of enhancing the clinical efficacy of treatment strategies. In metastatic breast cancer, <jats:italic>ARID1A<\/jats:italic> is the most prevalent mutation of the SWI\/SNF complex, which regulates DNA repair, recombination, and gene transcription. The low expression of <jats:italic>ARID1A<\/jats:italic> is associated with poor disease-free survival and overall survival of patients with luminal A or HER2-rich breast cancer. In addition, <jats:italic>ARID1A<\/jats:italic> plays a prominent role in maintaining luminal characteristics and has an advantage for identifying responses to treatment, including endocrine therapies, HDAC inhibitors and CDK4\/6 inhibitors. The therapeutic vulnerabilities initiated by <jats:italic>ARID1A<\/jats:italic> alterations encourage us to explore new approaches to cope with <jats:italic>ARID1A<\/jats:italic> mutant-related drug resistance or metastasis. In this review, we describe the mutation profiles of ARID1A in metastatic breast cancer and the structure and function of ARID1A and the SWI\/SNF complex as well as discuss the potential mechanisms of ARID1A-mediated endocrine resistance and therapeutic potential.<\/jats:p>","DOI":"10.3389\/fonc.2021.759577","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T06:29:14Z","timestamp":1636007354000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target"],"prefix":"10.3389","volume":"11","author":[{"given":"Xuan","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Xiong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Chen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"B1","unstructured":"World Cancer Day 2021: Spotlight on IARC Research Related to Breast Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive Molecular Portraits of Human Breast Tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"CD011276","DOI":"10.1002\/14651858.CD011276.pub2","article-title":"Breast Surgery for Metastatic Breast Cancer","volume":"3","author":"Tosello","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic Heterogeneity of Breast Cancer: Molecular Mechanism and Potential Therapeutic Targets","volume":"60","author":"Liang","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.semcancer.2015.08.009","article-title":"Clinical and Molecular Complexity of Breast Cancer Metastases","volume":"35","author":"Kimbung","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2016.11.005","article-title":"Comprehensive Genomic Sequencing and the Molecular Profiles of Clinically Advanced Breast Cancer","volume":"49","author":"Ross","year":"2017","journal-title":"Pathology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1056-z","article-title":"Genomic Characterization of Metastatic Breast Cancers","volume":"569","author":"Bertucci","year":"2019","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nrclinonc.2015.123","article-title":"Precision Medicine for Metastatic Breast Cancer\u2013Limitations and Solutions","volume":"12","author":"Arnedos","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 Mutations in Hormone-Resistant Metastatic Breast Cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.gde.2017.02.004","article-title":"Mammalian SWI\/SNF Complexes in Cancer: Emerging Therapeutic Opportunities","volume":"42","author":"St Pierre","year":"2017","journal-title":"Curr Opin Genet Dev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1945","article-title":"Chromatin Remodelling: The Industrial Revolution of DNA Around Histones","volume":"7","author":"Saha","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80315-9","article-title":"Reconstitution of a Core Chromatin Remodeling Complex From SWI\/SNF Subunits","volume":"3","author":"Phelan","year":"1999","journal-title":"Mol Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1128\/MCB.20.9.3137-3146.2000","article-title":"The Human SWI-SNF Complex Protein P270 Is an ARID Family Member With Non-Sequence-Specific DNA Binding Activity","volume":"20","author":"Dallas","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/nar\/gki145","article-title":"DNA-Binding Properties of ARID Family Proteins","volume":"33","author":"Patsialou","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20040524","article-title":"Two Related ARID Family Proteins Are Alternative Subunits of Human SWI\/SNF Complexes","volume":"383","author":"Wang","year":"2004","journal-title":"Biochem J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7541","DOI":"10.1128\/MCB.20.20.7541-7549.2000","article-title":"BRG-1 Is Recruited to Estrogen-Responsive Promoters and Cooperates With Factors Involved in Histone Acetylation","volume":"20","author":"Direnzo","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdf412","article-title":"Targeting of SWI\/SNF Chromatin Remodelling Complexes to Estrogen-Responsive Genes","volume":"21","author":"Belandia","year":"2002","journal-title":"EMBO J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210509","article-title":"Reprogramming of the SWI\/SNF Complex for Co-Activation or Co-Repression in Prohibitin-Mediated Estrogen Receptor Regulation","volume":"26","author":"Zhang","year":"2007","journal-title":"Oncogene"},{"key":"B19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and Bioinformatic Analysis of Mammalian SWI\/SNF Complexes Identifies Extensive Roles in Human Malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat Genet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e55119","DOI":"10.1371\/journal.pone.0055119","article-title":"The Spectrum of SWI\/SNF Mutations, Ubiquitous in Human Cancers","volume":"8","author":"Shain","year":"2013","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.23.8879-8888.2000","article-title":"A Specificity and Targeting Subunit of a Human SWI\/SNF Family-Related Chromatin-Remodeling Complex","volume":"20","author":"Nie","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.1196333","article-title":"Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2018.07.005","article-title":"ARID1A Mutant Ovarian Clear Cell Carcinoma: A Clear Target for Synthetic Lethal Strategies","volume":"1870","author":"Caumanns","year":"2018","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pharmthera.2018.05.001","article-title":"ARID1A Loss in Cancer: Towards a Mechanistic Understanding","volume":"190","author":"Mathur","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20459","article-title":"Genomic and Functional Evidence for an ARID1A Tumor Suppressor Role","volume":"46","author":"Huang","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0371-4","article-title":"ARID1A and CEBPalpha Cooperatively Inhibit UCA1 Transcription in Breast Cancer","volume":"37","author":"Guo","year":"2018","journal-title":"Oncogene"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0541-5","article-title":"ARID1A Influences HDAC1\/BRD4 Activity, Intrinsic Proliferative Capacity and Breast Cancer Treatment Response","volume":"52","author":"Nagarajan","year":"2020","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","article-title":"Genomic Evolution of Breast Cancer Metastasis and Relapse","volume":"32","author":"Yates","year":"2017","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.386","article-title":"An Integrated Genomic Approach Identifies ARID1A as a Candidate Tumor-Suppressor Gene in Breast Cancer","volume":"31","author":"Mamo","year":"2012","journal-title":"Oncogene"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202489","article-title":"Expression and Prognostic Values of ARID Family Members in Breast Cancer","volume":"13","author":"Zhang","year":"2021","journal-title":"Aging"},{"key":"B32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41588-019-0554-0","article-title":"ARID1A Determines Luminal Identity and Therapeutic Response in Estrogen-Receptor-Positive Breast Cancer","volume":"52","author":"Xu","year":"2020","journal-title":"Nat Genet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/jca.16602","article-title":"Downregulation of ARID1A, A Component of the SWI\/SNF Chromatin Remodeling Complex, in Breast Cancer","volume":"8","author":"Takao","year":"2017","journal-title":"J Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-020-01379-3","article-title":"Acquired Mutations and Transcriptional Remodeling in Long-Term Estrogen-Deprived Locoregional Breast Cancer Recurrences","volume":"23","author":"Priedigkeit","year":"2021","journal-title":"Breast Cancer Res BCR"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13551","article-title":"High-Level Expression of ARID1A Predicts a Favourable Outcome in Triple-Negative Breast Cancer Patients Receiving Paclitaxel-Based Chemotherapy","volume":"22","author":"Lin","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1158\/1078-0432.CCR-15-2996","article-title":"Loss of ARID1A Activates ANXA1, Which Serves as a Predictive Biomarker for Trastuzumab Resistance","volume":"22","author":"Berns","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 10-Year Analysis of the ATAC Trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70270-4","article-title":"Assessment of Letrozole and Tamoxifen Alone and in Sequence for Postmenopausal Women With Steroid Hormone Receptor-Positive Breast Cancer: The BIG 1-98 Randomised Clinical Trial at 8\u00b71 Years Median Follow-Up","volume":"12","author":"Regan","year":"2011","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 Mg Versus Anastrozole 1 Mg for Hormone Receptor-Positive Advanced Breast Cancer (FALCON): An International, Randomised, Double-Blind, Phase 3 Trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.038","article-title":"Advances in Adjuvant Hormonal Therapy for Postmenopausal Women","volume":"23","author":"Strasser-Weippl","year":"2005","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30164-0","article-title":"Tucidinostat Plus Exemestane for Postmenopausal Patients With Advanced, Hormone Receptor-Positive Breast Cancer (ACE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"20","author":"Jiang","year":"2019","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2584","article-title":"Loss of Estrogen Receptor in Recurrent Breast Cancer Is Associated With Poor Response to Endocrine Therapy","volume":"14","author":"Kuukasj\u00e4rvi","year":"1996","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1101\/gad.7.3.331","article-title":"Direct Binding of Cyclin D to the Retinoblastoma Gene Product (pRb) and pRb Phosphorylation by the Cyclin D-Dependent Kinase CDK4","volume":"7","author":"Kato","year":"1993","journal-title":"Genes Dev"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, A Phase II Study of Abemaciclib, A CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients With Refractory HR(+)\/HER2(-) Metastatic Breast Cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The Cyclin-Dependent Kinase 4\/6 Inhibitor Palbociclib in Combination With Letrozole Versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, HER2-Negative, Advanced Breast Cancer (PALOMA-1\/TRIO-18): A Randomised Phase 2 Study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1225","article-title":"The P270 (ARID1A\/SMARCF1) Subunit of Mammalian SWI\/SNF-Related Complexes Is Essential for Normal Cell Cycle Arrest","volume":"65","author":"Nagl","year":"2005","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206818","article-title":"Cyclin-E Is a Strong Predictor of Endocrine Therapy Failure in Human Breast Cancer","volume":"22","author":"Span","year":"2003","journal-title":"Oncogene"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.28.5.1031","article-title":"Cytoplasmic P21waf1\/CIP1 Correlates With Akt Activation and Poor Response to Tamoxifen in Breast Cancer","volume":"28","author":"P\u00e9rez-Tenorio","year":"2006","journal-title":"Int J Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 Inhibitor Treatment for Patients With Hormone Receptor-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer: A US Food and Drug Administration Pooled Analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant Plus Palbociclib Versus Fulvestrant Plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"eaax6367","DOI":"10.1126\/science.aax6367","article-title":"Structural Basis for Allosteric PARP-1 Retention on DNA Breaks","volume":"368","author":"Zandarashvili","year":"2020","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-Ribose) Polymerase Inhibition: Past, Present and Future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP Inhibitor Sensitivity and Resistance","volume":"71","author":"D'Andrea","year":"2018","journal-title":"DNA Repair (Amst)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer: A Proof-of-Concept Trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1\/2 Mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients With BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.093","article-title":"A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated With PARP Inhibitor Resistance","volume":"23","author":"Hu","year":"2018","journal-title":"Cell Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1101\/gad.10.19.2423","article-title":"The Atr and Atm Protein Kinases Associate With Different Sites Along Meiotically Pairing Chromosomes","volume":"10","author":"Keegan","year":"1996","journal-title":"Genes Dev"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1101\/gad.842500","article-title":"Requirement for Atr in Phosphorylation of Chk1 and Cell Cycle Regulation in Response to DNA Replication Blocks and UV-Damaged DNA in Xenopus Egg Extracts","volume":"14","author":"Guo","year":"2000","journal-title":"Genes Dev"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1101\/gad.14.12.1448","article-title":"Chk1 Is an Essential Kinase That Is Regulated by Atr and Required for the G2\/M DNA Damage Checkpoint","volume":"14","author":"Liu","year":"2000","journal-title":"Genes Dev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The ATM Protein Kinase: Regulating the Cellular Response to Genotoxic Stress, and More","volume":"14","author":"Shiloh","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122622","article-title":"Inhibiting Wee1 and ATR Kinases Produces Tumor-Selective Synthetic Lethality and Suppresses Metastasis","volume":"129","author":"Bukhari","year":"2019","journal-title":"J Clin Invest"},{"key":"B69","doi-asserted-by":"publisher","first-page":"13837","DOI":"10.1038\/ncomms13837","article-title":"ATR Inhibitors as a Synthetic Lethal Therapy for Tumours Deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17111849","article-title":"The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins","volume":"17","author":"Taniguchi","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(01)03309-9","article-title":"Bromodomain: An Acetyl-Lysine Binding Domain","volume":"513","author":"Zeng","year":"2002","journal-title":"FEBS Lett"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01341-10","article-title":"The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3","volume":"31","author":"Rahman","year":"2011","journal-title":"Mol Cell Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0705053104","article-title":"Conserved P-TEFb-Interacting Domain of BRD4 Inhibits HIV Transcription","volume":"104","author":"Bisgrove","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku449","article-title":"Brd4 Activates P-TEFb for RNA Polymerase II CTD Phosphorylation","volume":"42","author":"Itzen","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.modgep.2004.03.002","article-title":"Identification of Unique, Differentiation Stage-Specific Patterns of Expression of the Bromodomain-Containing Genes Brd2, Brd3, Brd4, and Brdt in the Mouse Testis","volume":"4","author":"Shang","year":"2004","journal-title":"Gene Expression Patterns"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2014.124","article-title":"BRD4 Regulates Nanog Expression in Mouse Embryonic Stem Cells and Preimplantation Embryos","volume":"21","author":"Liu","year":"2014","journal-title":"Cell Death Differ"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.11.3794-3802.2002","article-title":"Growth and Early Postimplantation Defects in Mice Deficient for the Bromodomain-Containing Protein Brd4","volume":"22","author":"Houzelstein","year":"2002","journal-title":"Mol Cell Biol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710331105","article-title":"Bromodomain 4 Activation Predicts Breast Cancer Survival","volume":"105","author":"Crawford","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-4417","article-title":"Deletion of the Proline-Rich Region of the Murine Metastasis Susceptibility Gene Brd4 Promotes Epithelial-to-Mesenchymal Transition- and Stem Cell-Like Conversion","volume":"71","author":"Alsarraj","year":"2011","journal-title":"Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.molcel.2020.04.034","article-title":"Opposing Functions of BRD4 Isoforms in Breast Cancer","volume":"78","author":"Wu","year":"2020","journal-title":"Mol Cell"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2014.71","article-title":"An Epigenomic Approach to Therapy for Tamoxifen-Resistant Breast Cancer","volume":"24","author":"Feng","year":"2014","journal-title":"Cell Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.06.016","article-title":"Bromodomain Protein BRD4 Is Required for Estrogen Receptor-Dependent Enhancer Activation and Gene Transcription","volume":"8","author":"Nagarajan","year":"2014","journal-title":"Cell Rep"},{"key":"B83","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cell.2015.11.062","article-title":"Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance","volume":"164","author":"Marcotte","year":"2016","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.028","article-title":"Disrupting the Interaction of BRD4 With Diacetylated Twist Suppresses Tumorigenesis in Basal-Like Breast Cancer","volume":"25","author":"Shi","year":"2014","journal-title":"Cancer Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nature16508","article-title":"Response and Resistance to BET Bromodomain Inhibitors in Triple-Negative Breast Cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0559","article-title":"BRD4 Regulates Breast Cancer Dissemination Through Jagged1\/Notch1 Signaling","volume":"76","author":"Andrieu","year":"2016","journal-title":"Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1720000115","article-title":"Spatially Constrained Tandem Bromodomain Inhibition Bolsters Sustained Repression of BRD4 Transcriptional Activity for TNBC Cell Growth","volume":"115","author":"Ren","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric Molecules That Target Proteins to the Skp1-Cullin-F Box Complex for","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem Biol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31898","article-title":"BET Proteins Regulate Homologous Recombination-Mediated DNA Repair: BRCAness and Implications for Cancer Therapy","volume":"144","author":"Mio","year":"2019","journal-title":"Int J Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2019.08.008","article-title":"Class I Histone Deacetylase Inhibition Is Synthetic Lethal With BRCA1 Deficiency in Breast Cancer Cells","volume":"10","author":"Zhang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5601","article-title":"Induction of USP17 by Combining BET and HDAC Inhibitors in Breast Cancer Cells","volume":"6","author":"Borbely","year":"2015","journal-title":"Oncotarget"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.337","article-title":"Identification of a Cancer Stem Cell-Specific Function for the Histone Deacetylases, HDAC1 and HDAC7, in Breast and Ovarian Cancer","volume":"36","author":"Witt","year":"2017","journal-title":"Oncogene"},{"key":"B94","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1038\/ncomms6406","article-title":"BRMS1L Suppresses Breast Cancer Metastasis by Inducing Epigenetic Silence of FZD10","volume":"5","author":"Gong","year":"2014","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1993.tb06112.x","article-title":"A Human Homologue of Saccharomyces Cerevisiae SNF2\/SWI2 and Drosophila Brm Genes Potentiates Transcriptional Activation by the Glucocorticoid Receptor","volume":"12","author":"Muchardt","year":"1993","journal-title":"EMBO J"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/366170a0","article-title":"BRG1 Contains a Conserved Domain of the SWI2\/SNF2 Family Necessary for Normal Mitotic Growth and Transcription","volume":"366","author":"Khavari","year":"1993","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1002\/j.1460-2075.1996.tb00921.x","article-title":"Purification and Biochemical Heterogeneity of the Mammalian SWI-SNF Complex","volume":"15","author":"Wang","year":"1996","journal-title":"EMBO J"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1323805","article-title":"PBAF Chromatin-Remodeling Complex Requires a Novel Specificity Subunit, BAF200, to Regulate Expression of Selective Interferon-Responsive Genes","volume":"19","author":"Yan","year":"2005","journal-title":"Genes Dev"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3480","article-title":"ARID1B Is a Specific Vulnerability in ARID1A-Mutant Cancers","volume":"20","author":"Helming","year":"2014","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"18207","DOI":"10.1038\/s41598-019-54757-z","article-title":"Targeting ARID1A-Mutant Colorectal Cancer: Depletion of ARID1B Increases Radiosensitivity and Modulates DNA Damage Response","volume":"9","author":"Niedermaier","year":"2019","journal-title":"Sci Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061710","article-title":"ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma","volume":"19","author":"Sato","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e30506","DOI":"10.7554\/eLife.30506","article-title":"Chromatin Accessibility Underlies Synthetic Lethality of SWI\/SNF Subunits in ARID1A-Mutant Cancers","volume":"6","author":"Kelso","year":"2017","journal-title":"Elife"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/his.12701","article-title":"Clinicopathological Significance of ARID1B in Breast Invasive Ductal Carcinoma","volume":"67","author":"Shao","year":"2015","journal-title":"Histopathology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.9961","article-title":"Upregulated Expression of AT-Rich Interactive Domain-Containing Protein 1B Predicts Poor Prognosis in Patients With Triple-Negative Breast Cancer","volume":"17","author":"Cui","year":"2019","journal-title":"Oncol Lett"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cell.2018.09.032","article-title":"Modular Organization and Assembly of SWI\/SNF Family Chromatin Remodeling Complexes","volume":"175","author":"Mashtalir","year":"2018","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1331","article-title":"Targeted Disruption of the EZH2-EED Complex Inhibits EZH2-Dependent Cancer","volume":"9","author":"Kim","year":"2013","journal-title":"Nat Chem Biol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"e000438","DOI":"10.1136\/jitc-2019-000438","article-title":"ARID1A Alterations Function as a Biomarker for Longer Progression-Free Survival After Anti-PD-1\/PD-L1 Immunotherapy","volume":"8","author":"Okamura","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B108","doi-asserted-by":"publisher","first-page":"eabc4220","DOI":"10.1126\/scitranslmed.abc4220","article-title":"ARID1A Mutation Plus CXCL13 Expression Act as Combinatorial Biomarkers to Predict Responses to Immune Checkpoint Therapy in mUCC","volume":"12","author":"Goswami","year":"2020","journal-title":"Sci Trans Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10020-020-00208-9","article-title":"Subunits of ARID1 Serve as Novel Biomarkers for the Sensitivity to Immune Checkpoint Inhibitors and Prognosis of Advanced Non-Small Cell Lung Cancer","volume":"26","author":"Sun","year":"2020","journal-title":"Mol Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A Deficiency Promotes Mutability and Potentiates Therapeutic Antitumor Immunity Unleashed by Immune Checkpoint Blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular Classification and Therapeutic Targets in Extrahepatic Cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J Hepatol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2404","article-title":"ARID1A Mutation May Define an Immunologically Active Subgroup in Patients With Microsatellite Stable Colorectal Cancer","volume":"27","author":"Mehrvarz Sarshekeh","year":"2021","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070678","article-title":"ARID1A Mutations Are Associated With Increased Immune Activity in Gastrointestinal Cancer","volume":"8","author":"Li","year":"2019","journal-title":"CellsV"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e001437","DOI":"10.1136\/jitc-2020-001437","article-title":"Analysis of the Molecular Nature Associated With Microsatellite Status in Colon Cancer Identifies Clinical Implications for Immunotherapy","volume":"8","author":"Bao","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1172\/JCI130445","article-title":"Inhibition of the ATM\/Chk2 Axis Promotes cGAS\/STING Signaling in ARID1A-Deficient Tumors","volume":"130","author":"Wang","year":"2020","journal-title":"J Clin Invest"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1302","article-title":"HDAC6 Inhibition Synergizes With Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer","volume":"79","author":"Fukumoto","year":"2019","journal-title":"Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ccell.2018.12.009","article-title":"Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers","volume":"35","author":"Ogiwara","year":"2019","journal-title":"Cancer Cell"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008202723066","article-title":"Breast Cancer: Pretreatment Drug Resistance Parameters (GSH-System, ATase, P-Glycoprotein) in Tumor Tissue and Their Correlation With Clinical and Prognostic Characteristics","volume":"8","author":"Buser","year":"1997","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.09.002","article-title":"NIR-Light and GSH Activated Cytosolic P65-shRNA Delivery for Precise Treatment of Metastatic Cancer","volume":"288","author":"Wang","year":"2018","journal-title":"J Control Release"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32742","article-title":"LEF1 Supports Metastatic Brain Colonization by Regulating Glutathione Metabolism and Increasing ROS Resistance in Breast Cancer","volume":"146","author":"Blazquez","year":"2020","journal-title":"Int J Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1039\/C7NR00962C","article-title":"Redox and pH Dual Sensitive Bone Targeting Nanoparticles to Treat Breast Cancer Bone Metastases and Inhibit Bone Resorption","volume":"9","author":"Zhao","year":"2017","journal-title":"Nanoscale"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3799","article-title":"Synthetic Lethality by Targeting EZH2 Methyltransferase Activity in ARID1A-Mutated Cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00975-3","article-title":"Drosophila Enhancer of Zeste\/ESC Complexes Have a Histone H3 Methyltransferase Activity That Marks Chromosomal Polycomb Sites","volume":"111","author":"Czermin","year":"2002","journal-title":"Cell"},{"key":"B124","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0092-8674(02)00976-5","article-title":"Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex","volume":"111","author":"M\u00fcller","year":"2002","journal-title":"Cell"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.311","article-title":"EZH2 Contributes to the Response to PARP Inhibitors Through Its PARP-Mediated Poly-ADP Ribosylation in Breast Cancer","volume":"37","author":"Yamaguchi","year":"2018","journal-title":"Oncogene"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134402","article-title":"Epigenetic Driver Mutations in ARID1A Shape Cancer Immune Phenotype and Immunotherapy","volume":"130","author":"Li","year":"2020","journal-title":"J Clin Invest"},{"key":"B127","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ccr.2010.10.035","article-title":"EZH2 Promotes Expansion of Breast Tumor Initiating Cells Through Activation of RAF1-Beta-Catenin Signaling","volume":"19","author":"Chang","year":"2011","journal-title":"Cancer Cell"},{"key":"B128","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1073\/pnas.1933744100","article-title":"EZH2 Is a Marker of Aggressive Breast Cancer and Promotes Neoplastic Transformation of Breast Epithelial Cells","volume":"81","author":"Kleer","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"B129","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/0008-5472.CAN-20-0360","article-title":"NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression","volume":"81","author":"Jeong","year":"2021","journal-title":"Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.09.010","article-title":"FOXK2 Elicits Massive Transcription Repression and Suppresses the Hypoxic Response and Breast Cancer Carcinogenesis","volume":"30","author":"Shan","year":"2016","journal-title":"Cancer Cell"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3326","article-title":"The EZH2-PHACTR2-AS1-Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer","volume":"80","author":"Chu","year":"2020","journal-title":"Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"e2014408118","DOI":"10.1073\/pnas.2014408118","article-title":"Interplay Between Desmoglein2 and Hypoxia Controls Metastasis in Breast Cancer","volume":"118","author":"Chang","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3546","article-title":"Polycomb Protein EZH2 Regulates Tumor Invasion via the Transcriptional Repression of the Metastasis Suppressor RKIP in Breast and Prostate Cancer","volume":"72","author":"Ren","year":"2012","journal-title":"Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1308953111","article-title":"EZH2 Expands Breast Stem Cells Through Activation of NOTCH1 Signaling","volume":"111","author":"Gonzalez","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B135","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1038\/s41467-020-19704-x","article-title":"EZH2-Mediated PP2A Inactivation Confers Resistance to HER2-Targeted Breast Cancer Therapy","volume":"11","author":"Bao","year":"2020","journal-title":"Nat Commun"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1493","article-title":"Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer","volume":"10","author":"Deblois","year":"2020","journal-title":"Cancer Discov"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu391","article-title":"High Protein Expression of EZH2 Is Related to Unfavorable Outcome to Tamoxifen in Metastatic Breast Cancer","volume":"25","author":"Reijm","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1327","article-title":"Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERalpha-GREB1 Transcriptional Axis","volume":"78","author":"Wu","year":"2018","journal-title":"Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","first-page":"229ra41","DOI":"10.1126\/scitranslmed.3008326","article-title":"Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer","volume":"6","author":"Pathiraja","year":"2014","journal-title":"Sci Trans Med"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.devcel.2021.03.008","article-title":"The Bone Microenvironment Increases Phenotypic Plasticity of ER(+) Breast Cancer Cells","volume":"56","author":"Bado","year":"2021","journal-title":"Dev Cell"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41467-018-04864-8","article-title":"Targeting EZH2 Reactivates a Breast Cancer Subtype-Specific Anti-Metastatic Transcriptional Program","volume":"9","author":"Hirukawa","year":"2018","journal-title":"Nat Commun"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.118","article-title":"MEK-ERK Pathway Regulates EZH2 Overexpression in Association With Aggressive Breast Cancer Subtypes","volume":"30","author":"Fujii","year":"2011","journal-title":"Oncogene"},{"key":"B143","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/cdd.2016.95","article-title":"The Degradation of EZH2 Mediated by lncRNA ANCR Attenuated the Invasion and Metastasis of Breast Cancer","volume":"24","author":"Li","year":"2017","journal-title":"Cell Death Differ"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.celrep.2019.10.004","article-title":"Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis","volume":"29","author":"Zeng","year":"2019","journal-title":"Cell Rep"},{"key":"B145","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1038\/s41467-019-13105-5","article-title":"CDK2-Mediated Site-Specific Phosphorylation of EZH2 Drives and Maintains Triple-Negative Breast Cancer","volume":"10","author":"Nie","year":"2019","journal-title":"Nat Commun"},{"key":"B146","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.molcel.2017.12.024","article-title":"Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function","volume":"69","author":"Wan","year":"2018","journal-title":"Mol Cell"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-00615-9","article-title":"Methylation of EZH2 by PRMT1 Regulates Its Stability and Promotes Breast Cancer Metastasis","volume":"27","author":"Li","year":"2020","journal-title":"Cell Death Differ"},{"key":"B148","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1038\/s41467-018-05078-8","article-title":"P38-Mediated Phosphorylation at T367 Induces EZH2 Cytoplasmic Localization to Promote Breast Cancer Metastasis","volume":"9","author":"Anwar","year":"2018","journal-title":"Nat Commun"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.molcel.2020.04.027","article-title":"Synthetic Lethal and Resistance Interactions With BET Bromodomain Inhibitors in Triple-Negative Breast Cancer","volume":"78","author":"Shu","year":"2020","journal-title":"Mol Cell"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 Inhibition Triggers Anti-Tumour Immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"B151","doi-asserted-by":"publisher","first-page":"112034","DOI":"10.1016\/j.yexcr.2020.112034","article-title":"BRD4 Inhibition Suppresses PD-L1 Expression in Triple-Negative Breast Cancer","volume":"392","author":"Jing","year":"2020","journal-title":"Exp Cell Res"},{"key":"B152","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1016\/j.celrep.2019.10.093","article-title":"A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2","volume":"29","author":"Xu","year":"2019","journal-title":"Cell Rep"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4553","article-title":"Exploiting Replicative Stress to Treat Cancer","volume":"14","author":"Dobbelstein","year":"2015","journal-title":"Nat Rev Drug Discov"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.759577\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T06:29:17Z","timestamp":1636007357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.759577\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":153,"alternative-id":["10.3389\/fonc.2021.759577"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.759577","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"article-number":"759577"}}